Dapo Ilo

510 total citations
34 papers, 355 citations indexed

About

Dapo Ilo is a scholar working on Genetics, Epidemiology and Oncology. According to data from OpenAlex, Dapo Ilo has authored 34 papers receiving a total of 355 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Genetics, 22 papers in Epidemiology and 8 papers in Oncology. Recurrent topics in Dapo Ilo's work include Inflammatory Bowel Disease (24 papers), Microscopic Colitis (21 papers) and Colorectal Cancer Treatments and Studies (7 papers). Dapo Ilo is often cited by papers focused on Inflammatory Bowel Disease (24 papers), Microscopic Colitis (21 papers) and Colorectal Cancer Treatments and Studies (7 papers). Dapo Ilo collaborates with scholars based in United States, Canada and United Kingdom. Dapo Ilo's co-authors include Wen Zhou, Silvio Danese, Yuri Sánchez González, Remo Panaccione, Xuan Yao, Séverine Vermeire, Peter Higgins, Edward V. Loftus, M. A. Cotter and Christopher Fry and has published in prestigious journals such as Gastroenterology, The American Journal of Gastroenterology and European Urology.

In The Last Decade

Dapo Ilo

30 papers receiving 353 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dapo Ilo United States 12 230 165 80 55 52 34 355
M. C. Bishop United Kingdom 11 50 0.2× 41 0.2× 93 1.2× 19 0.3× 16 0.3× 20 346
Francesca Bredin United Kingdom 7 364 1.6× 238 1.4× 115 1.4× 216 3.9× 50 1.0× 8 546
Paulo Caldeira Portugal 10 131 0.6× 99 0.6× 73 0.9× 56 1.0× 3 0.1× 19 246
R. Bardi Tunisia 12 96 0.4× 40 0.2× 110 1.4× 148 2.7× 39 0.8× 54 412
Ahmed Ali Egypt 11 43 0.2× 33 0.2× 91 1.1× 29 0.5× 9 0.2× 32 273
Gareth Seaward Canada 8 37 0.2× 47 0.3× 108 1.4× 70 1.3× 16 0.3× 16 679
Eun Hye Oh South Korea 12 226 1.0× 222 1.3× 163 2.0× 45 0.8× 15 0.3× 54 466
Eugenio Volpi Italy 14 57 0.2× 47 0.3× 152 1.9× 20 0.4× 5 0.1× 37 702
Jenny Griffith United States 12 97 0.4× 75 0.5× 24 0.3× 95 1.7× 60 1.2× 39 286
Norman Junge Germany 14 82 0.4× 145 0.9× 160 2.0× 23 0.4× 7 0.1× 42 468

Countries citing papers authored by Dapo Ilo

Since Specialization
Citations

This map shows the geographic impact of Dapo Ilo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dapo Ilo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dapo Ilo more than expected).

Fields of papers citing papers by Dapo Ilo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dapo Ilo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dapo Ilo. The network helps show where Dapo Ilo may publish in the future.

Co-authorship network of co-authors of Dapo Ilo

This figure shows the co-authorship network connecting the top 25 collaborators of Dapo Ilo. A scholar is included among the top collaborators of Dapo Ilo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dapo Ilo. Dapo Ilo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Reinisch, Walter, Kamal Patel, Natalia Borruel, et al.. (2023). P658 Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect Comparison. Journal of Crohn s and Colitis. 17(Supplement_1). i785–i786. 2 indexed citations
2.
Panaccione, Remo, Eric B. Collins, Gil Melmed, et al.. (2023). Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis. Crohn s & Colitis 360. 5(2). otad009–otad009. 37 indexed citations
3.
Panaccione, Remo, Silvio Danese, Wen Zhou, et al.. (2023). Efficacy and safety of upadacitinib for 16‐week extended induction and 52‐week maintenance therapy in patients with moderately to severely active ulcerative colitis. Alimentary Pharmacology & Therapeutics. 59(3). 393–408. 16 indexed citations
4.
Danese, Silvio, Geert D’Haens, David T. Rubin, et al.. (2023). Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data. Inflammatory Bowel Diseases. 29(11). 1723–1729. 16 indexed citations
5.
Panés, Julián, Edward V. Loftus, Peter Higgins, et al.. (2023). Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results. Inflammatory Bowel Diseases. 29(9). 1421–1430. 9 indexed citations
6.
7.
Feagan, Brian G., Gareth Parkes, Pascal Juillerat, et al.. (2023). P52 Benefits of high versus low dose upadacitinib as maintenance treatment in ulcerative colitis. Poster presentations. A72.2–A73. 1 indexed citations
8.
Panés, Julián, et al.. (2023). Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis. Digestive Diseases and Sciences. 68(6). 2318–2332. 5 indexed citations
9.
Parkes, Gareth, Ryan C. Ungaro, Silvio Danese, et al.. (2023). Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis. Journal of Gastroenterology. 58(10). 990–1002. 11 indexed citations
10.
Vermeire, Séverine, J F Colombel, Ken Takeuchi, et al.. (2022). DOP38 Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1. Journal of Crohn s and Colitis. 16(Supplement_1). i087–i088. 10 indexed citations
11.
Loftus, Edward V., Jean‐Frédéric Colombel, Ken Takeuchi, et al.. (2022). Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment. Clinical Gastroenterology and Hepatology. 21(9). 2347–2358.e6. 60 indexed citations
12.
Panaccione, Remo, Millie D. Long, Zhihua Ran, et al.. (2022). S805 Efficacy of Upadacitinib Dose Escalation in a Phase 3 Long-Term Extension Ulcerative Colitis Study. The American Journal of Gastroenterology. 117(10S). e574–e575. 3 indexed citations
13.
Vermeire, Séverine, Silvio Danese, Xuan Yao, et al.. (2022). S740 Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Final Results From the Phase 3 U-ACHIEVE Maintenance Study. The American Journal of Gastroenterology. 117(10S). e521–e522.
14.
15.
16.
Higgins, Peter, J F Colombel, Dapo Ilo, et al.. (2022). DOP39 Effect of baseline disease characteristics on clinical outcomes in moderate-to-severe Ulcerative Colitis treated with upadacitinib: Results from a Phase 3 trials programme. Journal of Crohn s and Colitis. 16(Supplement_1). i088–i089. 5 indexed citations
17.
Panaccione, Remo, Eric B. Collins, Gil Melmed, et al.. (2022). OP34 Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis. Journal of Crohn s and Colitis. 16(Supplement_1). i037–i041. 4 indexed citations
18.
Vermeire, Séverine, Satoshi Tanida, Remo Panaccione, et al.. (2021). S856 Efficacy of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis by Biologic Inadequate Responder Status: Results From Two Randomized Phase 3 Studies. The American Journal of Gastroenterology. 116(1). S399–S400. 4 indexed citations
19.
Blauvelt, Andrew, Kim Papp, C.E.M. Griffiths, et al.. (2017). Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). American Journal of Clinical Dermatology. 18(2). 273–280. 31 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. C. Bishop Breakdown of academic impact, for papers by Francesca Bredin Breakdown of academic impact, for papers by Paulo Caldeira Breakdown of academic impact, for papers by R. Bardi Breakdown of academic impact, for papers by Ahmed Ali Breakdown of academic impact, for papers by Gareth Seaward Breakdown of academic impact, for papers by Eun Hye Oh Breakdown of academic impact, for papers by Eugenio Volpi Breakdown of academic impact, for papers by Jenny Griffith Breakdown of academic impact, for papers by Norman Junge
Rankless by CCL
2026